150 related articles for article (PubMed ID: 20826695)
1. Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.
Hofmann-Sieber H; Wild J; Fiedler N; Tischer K; von Einem J; Osterrieder N; Hofmann H; Köstler J; Wagner R
J Virol; 2010 Nov; 84(22):11602-13. PubMed ID: 20826695
[TBL] [Abstract][Full Text] [Related]
2. Potential of equine herpesvirus 1 as a vector for immunization.
Trapp S; von Einem J; Hofmann H; Köstler J; Wild J; Wagner R; Beer M; Osterrieder N
J Virol; 2005 May; 79(9):5445-54. PubMed ID: 15827159
[TBL] [Abstract][Full Text] [Related]
3. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
4. The alpha-TIF (VP16) homologue (ETIF) of equine herpesvirus 1 is essential for secondary envelopment and virus egress.
von Einem J; Schumacher D; O'Callaghan DJ; Osterrieder N
J Virol; 2006 Mar; 80(6):2609-20. PubMed ID: 16501071
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
[TBL] [Abstract][Full Text] [Related]
6. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.
Schnabel CL; Babasyan S; Rollins A; Freer H; Wimer CL; Perkins GA; Raza F; Osterrieder N; Wagner B
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462575
[TBL] [Abstract][Full Text] [Related]
7. Growth of recombinant equine herpesvirus 1 (EHV-1) replaced with passage-induced mutant gene 1 and gene 71 derived from an attenuated EHV-1 in cell cultures and in the lungs of mice.
Kirisawa R; Kobayashi T; Uematsu R; Ikeda A; Kuroiwa R; Urakami A; Iwai H
Vet Microbiol; 2003 Sep; 95(3):159-74. PubMed ID: 12935744
[TBL] [Abstract][Full Text] [Related]
8. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).
Osterrieder N; Wagner R; Brandmüller C; Schmidt P; Wolf H; Kaaden OR
Virology; 1995 Apr; 208(2):500-10. PubMed ID: 7747423
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhea virus structural proteins.
Rosas CT; König P; Beer M; Dubovi EJ; Tischer BK; Osterrieder N
J Gen Virol; 2007 Mar; 88(Pt 3):748-757. PubMed ID: 17325347
[TBL] [Abstract][Full Text] [Related]
10. A vectored equine herpesvirus type 1 (EHV-1) vaccine elicits protective immune responses against EHV-1 and H3N8 equine influenza virus.
Van de Walle GR; May MA; Peters ST; Metzger SM; Rosas CT; Osterrieder N
Vaccine; 2010 Jan; 28(4):1048-55. PubMed ID: 19897066
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
12. Single dose adenovirus vectored vaccine induces a potent and long-lasting immune response against rabbit hemorrhagic disease virus after parenteral or mucosal administration.
Fernández E; Toledo JR; Chiong M; Parra F; Rodríguez E; Montero C; Méndez L; Capucci L; Farnós O
Vet Immunol Immunopathol; 2011 Aug; 142(3-4):179-88. PubMed ID: 21621855
[TBL] [Abstract][Full Text] [Related]
13. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
[TBL] [Abstract][Full Text] [Related]
14. Equine herpesvirus-1 strain KyA, a candidate vaccine strain, reduces viral titers in mice challenged with a pathogenic strain, RacL.
Colle CF; Tarbet EB; Grafton WD; Jennings SR; O'Callaghan DJ
Virus Res; 1996 Aug; 43(2):111-24. PubMed ID: 8864201
[TBL] [Abstract][Full Text] [Related]
15. Immunization with glycoprotein C of equine herpesvirus-1 is associated with accelerated virus clearance in a murine model.
Tewari D; Nair SV; De Ungria MC; Lawrence GL; Hayden M; Love DN; Field HJ; Whalley JM
Arch Virol; 1995; 140(4):789-97. PubMed ID: 7794119
[TBL] [Abstract][Full Text] [Related]
16. A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naïve and infection-primed mice.
Ruitenberg KM; Walker C; Love DN; Wellington JE; Whalley JM
Vaccine; 2000 Jan; 18(14):1367-73. PubMed ID: 10618534
[TBL] [Abstract][Full Text] [Related]
17. Pathogenicity and immunogenicity of equine herpesvirus type 1 mutants defective in either gI or gE gene in murine and hamster models.
Tsujimura K; Yamanaka T; Kondo T; Fukushi H; Matsumura T
J Vet Med Sci; 2006 Oct; 68(10):1029-38. PubMed ID: 17085880
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells presenting equine herpesvirus-1 antigens induce protective anti-viral immunity.
Steinbach F; Borchers K; Ricciardi-Castagnoli P; Ludwig H; Stingl G; Elbe-Bürger A
J Gen Virol; 1998 Dec; 79 ( Pt 12)():3005-14. PubMed ID: 9880015
[TBL] [Abstract][Full Text] [Related]
19. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of foals with a modified live, equid herpesvirus-1 gM deletion mutant (RacHΔgM) confers partial protection against infection.
Kydd JH; Hannant D; Robinson RS; Bryant N; Osterrieder N
Vaccine; 2020 Jan; 38(2):388-398. PubMed ID: 31629571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
